An Investigation Of The Neuroprotective Effects Of Palm Vitamin E Tocotrienols Using White Matter Lesions As The Human Study Model by Yogheswaran, Gopalan
i 
 
AN INVESTIGATION OF THE NEUROPROTECTIVE EFFECTS OF PALM 
VITAMIN E TOCOTRIENOLS USING WHITE MATTER LESIONS AS THE 
HUMAN STUDY MODEL 
 
 
 
by 
 
 
YOGHESWARAN GOPALAN 
 
 
 
 
 
Thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy 
 
 
September 2014 
 
 
 
 
ii 
 
DEDICATIONS 
 
This thesis is dedicated to the Almighty God for giving me the strength to complete my 
PhD, my beloved wife, Dr. Shubashini Gnanasan for her continuous support and 
inspiration, my adorable sons, Prakaladhan and Sithaarthan who are always there to 
cheer me up and to my wonderful parents, Mr. L. Gopalan and Madam M. Sathiamah for 
their everlasting encouragement and blessings on me. Thank you. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGEMENTS 
 
There are so many people without whom this project would not have been possible who 
I would like to thank. 
I would like to express my deepest and heartfelt gratitude to my supervisor, Professor 
Dr. Yuen Kah Hay who has given me the opportunity to pursue this project under his 
supervision. Indeed, I have gained tremendously in terms of academic excellence and 
persistence to achieve goals under his guidance which I will treasure throughout my life. 
My sincere appreciation to my co-supervisor Dr. Nurzalina Abdul Karim Khan for her 
constant assistance, suggestions and encouragement to complete my project.  
 I owe a deep gratitude to Professor Dr. Ibrahim Lutfi Shuaib. Without his support, I 
would not have been able to complete this study. I would also like to extend my heartfelt 
gratitude to  Dr. Mukhtar Alam Ansari and  the staff of Advanced Medical and Dental 
Institute, USM and Kepala Batas hospital for assisting me during the MRI imaging and 
data collection process. Also not forgetting, Mr. Ong Kok Haur for the excellent work on 
the MRI analysis. 
I would like thank the Malaysian Palm Oil Board for the financial support provided to 
conduct this project. Similar appreciation goes to Universiti Teknologi MARA for 
providing me the scholarship to pursue my PhD. They have allowed me to fulfil my 
dream by providing the much needed financial support and time that was required to 
complete this study. 
iv 
 
I take this opportunity to thank my family members and friends for their abundance of 
love, encouragement and support. My family has and always will be the greatest pillar of 
support in my life. My colleagues who have been my best critiques, they were ever 
willing to help and their assistance has been invaluable. I would like to acknowledge all 
of them for their support, in particular Dr. Wong Jia Woei, Dr. Enrico Magosso and Mr. 
Tommy Julianto. Thank you. 
Last but not least, I would like to acknowledge all my dear friends Dr. Ng Bee Hong, Dr. 
Sandy Ong, Dr. Jiayuddin Khan, Dr. Choon Wai Yee, Dr. Lim Sheau Chin, Dr. Kam Li 
Ying, Dr. Mahmathi Karuppannan, Goh Song Thai, Cheah Mei Mei, Lim Ai Boey, 
Cheah Phaik Chin, Siew siew, Belle, Mei Ching, Gan and the rest of the lab staff for 
their constant support and encouragement and their hospitality throughout the study. 
Finally, a deep appreciation goes out to all the participants of this study. Without them 
this study would not have been possible. 
 
 
 
 
 
 
 
 
 
v 
 
TABLE OF CONTENT 
DEDICATIONS ............................................................................................................................. ii 
ACKNOWLEDGEMENTS .......................................................................................................... iii 
TABLE OF CONTENT ..................................................................................................................v 
LIST OF TABLE ............................................................................................................................x 
LIST OF FIGURE ......................................................................................................................... xi 
ABBREVIATIONS ..................................................................................................................... xii 
PUBLICATIONS ........................................................................................................................ xiv 
ABSTRAK .................................................................................................................................. xvi 
ABSTRACT .............................................................................................................................. xviii 
1. CHAPTER 1: INTRODUCTION ...........................................................................................1 
1.1. White Matter Lesion .......................................................................................................1 
1.1.1. Introduction .................................................................................................................1 
1.1.2. Etiology of White Matter Lesion ................................................................................2 
1.1.3. Clinical Implication of White Matter Lesions .............................................................4 
1.2. Vitamin E ........................................................................................................................6 
1.2.1. Tocotrienol ..................................................................................................................6 
1.2.2. Neuroprotective Properties ..........................................................................................8 
1.2.3. Anti-atherogenic Properties ........................................................................................9 
1.2.4. Hypocholesterolemic effect of tocotrienols ..............................................................10 
1.2.5. Hypo-apolipoprotein B effect of tocotrienols ...........................................................12 
1.2.6. Hypo- lipoprotein Lp (a) effect of tocotrienols .........................................................13 
1.2.7. Antioxidant properties of tocotrienols.......................................................................14 
1.2.8. Inhibition of adhesion molecule expression and monocytic cell adherence by 
tocotrienols ................................................................................................................................15 
1.3. Clinical Evaluations: Basic Principles of Magnetic Resonance Imaging of the Brain .16 
1.4. Scope of the study .........................................................................................................18 
vi 
 
1.4.1. Primary Objective .....................................................................................................18 
1.4.2. Secondary Objectives ................................................................................................18 
2. CHAPTER 2: MAGNETIC RESONANCE ANGIOGRAPHY OF THE CAROTID 
ARTERY STENOSIS AMONG MILDLY HYPERCHOLESTEROLEMIC VOLUNTEERS ...19 
2.1. Introduction ...................................................................................................................19 
2.2. Materials and methods ..................................................................................................21 
2.2.1. Study Population .......................................................................................................21 
2.2.2. MRA Imaging Procedures .........................................................................................22 
2.2.3. Image Analysis ..........................................................................................................23 
2.2.4. Statistical Analysis ....................................................................................................24 
2.3. Results ...........................................................................................................................25 
2.3.1. Internal carotid artery stenosis ..................................................................................25 
2.3.2. Baseline Characteristics ............................................................................................26 
2.3.3. Demographic and disease profile ..............................................................................29 
2.4. Discussion .....................................................................................................................30 
2.5. Conclusion ....................................................................................................................31 
3. CHAPTER 3: PREVALENCE OF WHITE MATTER LESION (WML) IN A LOCAL 
HYPERCHOLESTEROLEMIC POPULATION IN NORTH –WEST PENINSULAR 
MALAYSIA..................................................................................................................................32 
3.1. Introduction ...................................................................................................................32 
3.2. Methods .........................................................................................................................34 
3.2.1. Study population .......................................................................................................34 
3.2.2. MRI scanning protocol ..............................................................................................34 
3.2.3. White matter lesion rating scale ................................................................................34 
3.2.4. Statistical Analysis ....................................................................................................36 
3.3. Results ...........................................................................................................................37 
3.4. Discussion .....................................................................................................................46 
3.5. Conclusion ....................................................................................................................48 
vii 
 
4. CHAPTER 4: THE NEUROPROTECTIVE EFFECTS OF PALM VITAMIN E 
TOCOTRIENOLS IN WHITE MATTER LESION NAIVE (MRI -VE) VOLUNTEERS ..........49 
4.1. Introduction ...................................................................................................................49 
4.2. Methods .........................................................................................................................52 
4.2.1. Study population .......................................................................................................52 
4.2.2. MRI scanning protocol ..............................................................................................53 
4.2.3. White matter lesion volumetric measurement ...........................................................53 
4.2.4. Randomization and Treatment ..................................................................................54 
4.2.5. Clinical evaluation ....................................................................................................55 
4.2.6. Statistical Analysis ....................................................................................................56 
4.3. Results ...........................................................................................................................57 
4.3.1. Volunteers flow and follow up ..................................................................................57 
4.3.2. Baseline characteristics and disease profile ..............................................................57 
4.3.3. WML development in MRI –ve volunteers ..............................................................60 
4.3.4. Clinical parameters ....................................................................................................62 
4.3.5. Compliance ...............................................................................................................65 
4.3.6. Adverse Events..........................................................................................................66 
4.4. Discussion .....................................................................................................................67 
4.5. Conclusion ....................................................................................................................69 
5. CHAPTER 5: NEUROPROTECTIVE EFFECTS OF PALM VITAMIN E 
TOCOTRIENOLS USING WHITE MATTER LESIONS AS THE HUMAN STUDY MODEL
 70 
5.1. Introduction ...................................................................................................................70 
5.2. Methods .........................................................................................................................74 
5.2.1. Study Protocol ...........................................................................................................74 
5.2.2. Study Population .......................................................................................................75 
5.2.3. Clinical Evaluation Procedures .................................................................................77 
5.2.4. MRI Imaging Parameters ..........................................................................................78 
viii 
 
5.2.5. White matter lesion volumetric measurement ...........................................................79 
5.2.6. Outcome measures ....................................................................................................80 
5.2.7. Statistical Analysis ....................................................................................................81 
5.3. Results ...........................................................................................................................83 
5.3.1. Volunteers flow and follow-up .................................................................................83 
5.3.2. Baseline Characteristics ............................................................................................85 
5.3.3. WML volume changes ..............................................................................................87 
5.3.4. Mean volume changes of WML for subjects with hypertension, diabetes or both 
hypertension and diabetes. ........................................................................................................90 
5.3.5. Clinical Parameters ...................................................................................................92 
5.3.6. Compliance ...............................................................................................................94 
5.3.7. Adverse Events..........................................................................................................95 
5.4. Discussion .....................................................................................................................96 
5.5. Conclusion ....................................................................................................................98 
6. CHAPTER 6: SUMMARY AND GENERAL CONCLUSIONS .......................................100 
7. CHAPTER 7: SUGGESTIONS FOR FURTHER RESEARCH ........................................104 
REFERENCES............................................................................................................................107 
APPENDICES ............................................................................................................................125 
Appendix 1- Mean WML volume changes (Intention to treat analysis) .....................................126 
Appendix 2: Mean WML volume changes (Per protocol analysis) ............................................129 
Appendix 4 - Plasma Tocotrienol Concentration in White Matter Lesion (MRI+ve) volunteers
 .....................................................................................................................................................133 
Appendix 5 - Plasma Tocotrienol Concentration in White Matter Lesion Naïve (MRI-ve) 
Volunteers ...................................................................................................................................136 
Appendix 6- Ethics Approval......................................................................................................139 
Appendix 7- Informed consent (Bahasa Malaysia) .....................................................................143 
Appendix 8- Informed consent (English) ....................................................................................152 
Appendix 9: Reference Range of Biochemistry Parameters .......................................................161 
ix 
 
Appendix 10: Previva certificate .................................................................................................163 
Appendix 11: Research publication ............................................................................................165 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
LIST OF TABLE 
Table 2.1: Baseline characteristics of 50 volunteers recruited into the study ...............................28 
Table 2.2: Demographic  and disease profile of study volunteers ................................................29 
Table 3.1: The ARWMC Rating Scale for MRI and CT ..............................................................35 
Table 3.2: Prevalence of White Matter Lesion among subjects screened .....................................38 
Table 3.3: White Matter Lesion distribution, frequency and score ...............................................39 
Table 3.4 Independent sample t-test comparing male and female with WML score, blood 
pressure, body mass index and biochemistry profile. ...................................................................41 
Table 3.5: Independent sample t-test comparing age group (above 50 years) and (below 50 years) 
with WML score, blood pressure, body mass index and biochemistry profile. ............................43 
Table 3.6: Results of Pearson correlation analysis ........................................................................45 
Table 4.1: Baseline characteristics of 28 volunteers who developed WML after 1 year ..............59 
Table 4.2: Health profiles of volunteers in the two study groups .................................................60 
Table 4.3: Blood biochemistry profile of research volunteers ......................................................63 
Table 5.1: Baseline characteristics of 121 volunteers recruited into the study .............................86 
Table 5.2: Mean volume changes of WML for subjects with hypertension, diabetes or both 
hypertension and diabetes. ............................................................................................................91 
Table 5.3: Blood biochemistry profile of research volunteers (Per Protocol Analysis) ................93 
 
 
 
 
 
 
 
 
 
 
xi 
 
LIST OF FIGURE 
Figure 1.1: Chemical structure of tocotrienols ...............................................................................7 
Figure 2.1: Diagram of an ICA stenosis illustrating measurement method (Adapted  fromNorth 
American Symptomatic Carotid Endartectomy Trial (NASCET) Steering Committee 1991) .....24 
Figure 2.2: The arrow shows a normal right internal carotid artery..............................................25 
Figure 2.3 : The arrow shows a normal left internal carotid artery ...............................................26 
Figure 4.1: Mean WML volume change (mm
3
) in volunteers who developed WMLs. ................62 
Figure 4.2: Mean total plasma tocotrienol concentrations of volunteers at baseline, 3, 6, 9, and 12 
months for T3 supplemented and placebo groups. ........................................................................66 
Figure 5.1: Participant flow chart ..................................................................................................84 
Figure 5.2: Mean WML volume change from baseline of tocotrienol-supplemented and placebo 
group using per-protocol analysis .................................................................................................89 
Figure 5.3: Mean WML volume change from baseline of tocotrienol-supplemented and placebo 
group using intention to treat analysis ..........................................................................................90 
Figure 5.4: Mean total plasma tocotrienol concentrations of volunteers at baseline, 3, 6, 9, 12 and 
24 months for tocotrienol-supplemented and placebo groups. .....................................................94 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
ABBREVIATIONS 
 
ALP  Alkaline Phosphatase 
ALT  Alanine Transaminase 
Apo B  Apolipoprotein B 
AST   Aspartate Aminotransferase 
BMI    Body Mass Index 
CCA  Common Carotid Artery 
CRT  Creatinine Kinase 
DSA   Digital Subtraction Angiography  
GGT  Gamma Glutamyl Transpeptidase 
HDL  High Density Lipoprtein 
Hs- CRP Highly Sensitive C Reactive Protein 
ICA  Internal Carotid Artery 
LDL  Low Density Lipoprotein 
LP (A)  Lipoprotein A 
MRA   Magnetic Resonance Angiography  
MRI  Magnetic Resonance Imaging 
T3  Mixed Tocotrienols 
TBARS   Thiobarbituric Acid Reactive Substance 
TC  Total Cholesterol 
xiii 
 
TG  Triglyceride 
USM    Universiti Sains Malaysia 
WML  White Matter Lesion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiv 
 
PUBLICATIONS 
 
Gopalan, Y., Shuaib, I.L., Magosso, E., Ansari, M.A., Rizal, M.A.B., Wong J.W., 
Khan, N.A.K., Leong, W.C., Sundram,K.,  Ng B.H., Chinna, K., & Yuen, K.H. 
(2014).Clinical Investigation of the Protective Effects of Palm Vitamin E 
Tocotrienols on Brain White Matter.Stroke; 45: 1422 – 1428. 
 
Gopalan, Y., Magosso, E., Shuaib, I.L., Ansari, M.A., Rizal, M.A.B., Khan, N.A.K.,  
Wong J.W., Ng B.H., Nesaretnam,K., Sundram,K, Chinna, K., & Yuen, K.H. 
(2012). Neuroprotective  Effects of Palm Vitamin E Tocotrienols in Brain White 
Matter Lesion : Evidence from A Double Blind Placebo – Controlled Clinical 
Trial.  Neuroepidemiology, 39:193. 
 
Gopalan, Y., Magosso, E., Shuaib, I.L., Ansari, M.A., Rizal, M.A.B., Khan, N.A.K.,  
Wong J.W., Ng B.H., Nesaretnam,K., Sundram,K & Yuen, K.H. (2011). 
Neuroprotective Effects of Tocotrienols in Brain White Matter Lesion : 
Preliminary Findings From A Clinical Trial. Paper presented at Palm 
International Nutra-Cosmeceutical Conference, Kuala Lumpur, Malaysia. (Poster 
presentation) 
 
Gopalan, Y., Magosso, E., Shuaib, I.L., Ansari, M.A., Rizal, M.A.B., Khan, N.A.K.,  
Wong J.W., Ng, B.H., Nesaretnam,K., Sundram,K & Yuen, K.H. (2011). An 
Insight into The Neuroprotective Effect of Tocotrienols Among White Matter 
Lesion Naïve Volunteers: A Preliminary Findings From A Double Blind Placebo 
Controlled Trial. Paper presented at 22
nd
 Annual Scientific Meeting of the 
Malaysian Society of Neurosciences, Kuala Terengganu, Terengganu, Malaysia. 
(Poster presentation) 
xv 
 
Magosso E, Gopalan Y, Yuen K.H. (2009). Antioxidant Supplements for Prevention of 
Mortality in Healthy Participants and Patients with Various Diseases (review) – 
Letter to the Editor. The Cochrane Library, 1:259-262. 
 
Gopalan, Y., Magosso, E., Shuaib, I.L., Ansari, M.A., Rizal, M.A.B., Khan, N.A.K.,  
Wong J.W., Ng B.H., Nesaretnam,K., Sundram,K & Yuen, K.H. (2009). Double 
Blind Placebo Controlled Study On The Neuroprotective And Anti -Atherogenic 
Effects  Of Palm Tocotrienol Rich Fraction (Palm Vitamin E). Paper presented at 
7
th
 COSTAM / SFRR (ASIA /MALAYSIA) International Workshop and 4
th
 
biennial meeting of SFRR ASIA, Langkawi, Malaysia (Poster presentation). 
 
Gopalan, Y. (2009). Prevalence of White Matter Lesion Among Adults In The North 
West Region Of Peninsular Malaysia. Paper presented at 9th Asian Conference 
on Clinical Pharmacy, Seoul, Korea. (Oral presentation) 
 
 
 
 
 
 
 
 
 
 
xvi 
 
SATU KAJIAN KESAN NEUROPROTEKTIF VITAMIN E TOKOTRIENOL 
MINYAK SAWIT MENGGUNAKAN KECEDERAAN ZON PUTIH OTAK 
SEBAGAI KAJIAN MODEL MANUSIA 
ABSTRAK 
Satu kajian telah dijalankan untuk menilai aktiviti neuroprotektif campuran tokotrienol 
menggunakan manusia yang mempunyai kecederaan zon putih otak [White matter lesion 
(WML)]. WMLs adalah manifestasi penyakit salur darah kecil cerebral. 
Di peringkat awal kajian, kesan anti arterogenik campuran tokotrienol di kalangan 
sukarelawan yang mempunyai paras kolesterol sederhana tinggi telah dinilai melalui 
pengimejan arteri karotid menggunakan Magnetic Resonance Angiography (MRA). 
Tiada sesiapapun daripada 50 sukarelawan pertama yang menjalani pengimejan tersebut 
mengalami stenosis arteri karotid. Oleh itu, bahagian kajian ini telah ditamatkan. 
Fasa kajian seterusnya, prevalens WML dikalangan populasi yang mempunyai paras 
kolesterol sederhana tinggi sekitar bahagian utara semenanjung Malaysia telah 
dikenalpasti.  Daripada 350 sukarelawan yang menjalani pengimejan, 161(46%) 
mempunyai WML, di mana 65 (18.6%) adalah lelaki dan 96 (27.4%) adalah wanita. 
Kajian ini juga telah menunjukkan peluang untuk mendapat WMLs adalah 2 kali ganda 
(30.6%) dalam lingkungan umur 50 keatas berbanding 15.4% dalam kumpulan umur 50 
kebawah. 
Dibahagian kajian neuroprotektif, kajian rawak rabun dua pihak plasebo terkawal telah 
dijalankan. Sukarelawan yang diambil adalah ≥ 35 tahun yang mempunyai risiko 
kardiovaskular dan menjalani Magnetic Resonance Imaging (MRI) otak. Mereka 
dikategorikan sebagai WML positif (MRI +ve) jika ada WML pada awal kajian. 
xvii 
 
Sukarelawan tanpa WML pada awal kajian akan diklasifikasikan (MRI -ve). Dalam 
kohort MRI-ve, 120 sukarelawan dirawakkan untuk menerima sama ada 200 mg 
campuran tokotrienol atau plasebo dua kali sehari dan disusuli selama setahun.  Daripada 
113 sukarelawan yang melengkapkan kajian, 19 daripada kumpulan campuran 
tokotrienol dan 9 dalam kumpulan plasebo membentuk WML baru. 
Walaubagaimanapun, purata pembentukan volum WML baru selepas setahun adalah 
lebih rendah dikalangan kumpulan campuran tokotrienol (8%) berbanding placebo 
(47%) dengan kesignifikan statistik  p = 0.048.  
Dibahagian akhir kajian, 121 sukarelawan yang disahkan WMLs (MRI+ve) telah 
dirawakkan untuk menerima 200 mg campuran tokotrienol atau plasebo dan disusuli 
selama 2 tahun. Berdasarkan analisa „per protocol‟(88 sukarelawan) dan „intention to 
treat‟(121 sukarelawan) purata volum WML kumpulan placebo meningkat selepas 2 
tahun, namun kumpulan yang menerima campuran tokotrienol  kekal tidak berubah. 
Purata perubahan volum WML diantara dua kumpulan adalah tidak signifikan pada akhir 
tahun pertama (p = 0.150) tetapi signifikan pada akhir tahun kedua untuk analisa „per 
protocol‟ dan „intention to treat‟(p = 0.019 dan p = 0.018). Dengan itu, kajian ini telah 
menunjukkan bahawa campuran tokotrienol boleh melemahkan perkembangan WMLs. 
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AN INVESTIGATION OF THE NEUROPROTECTIVE EFFECTS OF PALM 
VITAMIN E TOCOTRIENOLS USING WHITE MATTER LESIONS AS THE 
HUMAN STUDY MODEL 
ABSTRACT 
A study was conducted to evaluate the neuroprotective activity of mixed tocotrienols 
using human volunteers with white matter lesion (WML). WMLs are regarded as 
manifestations of cerebral small vessel disease.   
Initially, the anti atherogenic effect of mixed tocotrienols was also evaluated in mildly 
hypercholesterolemic volunteers via imaging the carotid arteries using Magnetic 
Resonance Angiography (MRA). Of the first 50 consecutive volunteers who undergone 
the carotid artery imaging, none of them were detected having carotid artery stenosis and 
hence this part of the study was discontinued. 
In the next phase of the study, the prevalence of white matter lesion (WML) in a local 
hypercholesterolemic population in north –west peninsular Malaysia was determined. Of 
the 350 research volunteers who were imaged, 161 (46%) of them had WMLs, of which 
65 (18.6%) were males and 96 (27.4%) females. The study also demonstrated that the 
chances of developing WMLs doubled (30.6%) in the age group of above 50 compared 
to 15.4% in the age group of below 50. 
In the neuroprotective part of the study, a randomized double-blind placebo-controlled 
trial was conducted. Volunteers recruited were ≥ 35 years with cardiovascular risk 
factors and undergo Magnetic Resonance Imaging (MRI) of the brain. They were 
categorized as WML positive (MRI +ve) if they were present with WML at baseline.  
xix 
 
Volunteers without WMLs at baseline were classified as (MRI -ve). In the MRI –ve 
cohort, 120 volunteers were randomized to receive either  200 mg mixed tocotrienols or 
placebo twice daily and were followed up for 1 year. Out of 113 volunteers who 
completed the study, 19 in the mixed tocotrienols and 9 in the placebo group developed 
new WMLs. However, the mean volume of the WMLs developed after 1 year was lesser 
in the mixed tocotrienol treated group (8%) compared to placebo (47%) with a statistical 
significance of p = 0.048.  
In the final part of the study, 121 volunteers with MRI confirmed WMLs (MRI +ve)  
were randomized to receive 200 mg mixed tocotrienols or placebo twice daily and were 
followed up for 2 years. According to per protocol (88 volunteers) and intention-to-treat 
(121 volunteers) analyses, the mean WML volume of the placebo group increased after 2 
years, whereas that of the mixed tocotrienol supplemented group remained essentially 
unchanged. The mean WML volume change between the two groups was not 
significantly different (p = 0.150) at the end of 1 year but was significant at the end of 2 
years for both per protocol and intention-to-treat analyses (p = 0.019 and p = 0.018). 
Thus, the present study found that mixed tocotrienols can attenuate the progression of 
WMLs.  
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1. CHAPTER 1: INTRODUCTION 
 
1.1. White Matter Lesion 
1.1.1. Introduction 
White matter lesions (WMLs) are areas of increased signal intensity detected on T2-
weighted magnetic resonance imaging (MRI) scans. These lesions are common among 
older adults (Brickman, Schupf, Manly, & et al., 2008)(F.-E. de Leeuw et al., 2001) and 
are thought to reflect small vessel vascular disease and neurodegeneration of nerve 
bundles.  WMLs  are  frequently  observed in  individuals  with  advanced  age,  
hypertension,  prior  ischemic stroke  and  other  cerebrovascular  risk  factors  (Hénon, 
Godefroy, Lucas, Pruvo, & Leys, 1996; Kalaria & Erkinjuntti, 2006; Leys et al., 1999; 
Räihä, Tarvonen, Kurki, Rajala, & Sourander, 1993; Wiszniewska, Devuyst, 
Bogousslavsky, Ghika, & van Melle, 2000). The white matter of the brain accounts for 
the 60% of the total brain volume. It includes major commissural tracts, the cortical 
association fibers, and all the cortical afferent and efferent fibers. White matter consists 
of nerve fibers, supporting cells, interstitial space and vascular structures. Axons are 
major component of white matter and it is enveloped by myelin with two types of 
neuroglia; oligodendrocytes and astrocytes. Myelin acts as an insulator of axons and its 
structure facilitates rapid transmission of impulses (Valk & van der Knaap, 1989). The 
role of white matter is in information transmission to connect various grey matters 
(neuron bodies) which is mainly responsible for information processing. 
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1.1.2. Etiology of White Matter Lesion 
Based on clinicopathological studies, WMLs can be classified into three different 
categories which includes  punctate, periventricular, and confluent WMLs and showed 
that at least one of these is due to small vessel disease (Fazekas et al., 1993 ). This 
affects arteries of 150μm in diameter and is generally associated with hypertension, 
diabetes, or both. The major vascular pathological finding is the one that Fisher in the 
1950s termed “segmental arterial wall disorganization” (Fisher, 1982) also widely 
known by others as lipohyalinosis (Ogata, 1999), where the loss of the arterial 
architecture consists of whorls, tangles or wisps of more or less fine connective tissue 
that entirely replaces the vessel wall and obliterates the normal vascular coats. The 
general outline of the vessel in less destructive lesions is preserved and the disintegrating 
wall consists in a loose meshwork of collagenous strands separated by empty interstitial 
clefts (Fisher, 1968). The foremost consequences of lipohyalinosis are small-vessel wall 
thickening and luminal narrowing which leads to arteriolosclerosis (Leonardo Pantoni & 
Julio H. Garcia, 1997; Wardlaw, Sandercock, Dennis, & Starr, 2003). The axonal 
damage that occurs within the confluent lesions is however variable, which involves 
demyelination with preservation of axonal integrity to complete axonal disruption with 
loss of axonal function (Fazekas et al., 1988). As a result of the degeneration of the 
neurons,   axonal disruption leads to functional loss of the affected network, while 
demyelination causes only slowing of stimulus speed conduction, hence at least in some 
cases WMLs may lead to reduced efficiency of the affected network, but with preserved 
function.  On the other hand, imaging-pathological studies have shown that punctate 
lesions can be related with variable pathological findings ranging from no detectable 
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pathology at all to enlargement of perivascular spaces (Fazekas, et al., 1993 ). In the case 
of discontinuation of the ependymal lining which results in permeation of water into the 
axons and chronic edema of the white matter adjacent to the ventricles, the condition is 
known as periventricular caps and halo but with no axonal damage (Fazekas, et al., 1993 
). Reduced blood flow was also evident in WMLs.  Cerebral blood flow was lower in 
WMH areas relative to normal appearing white matter, which in turn, was lower than 
grey matter. Regions with consistently lower cerebral blood flow across individuals were 
more likely to appear as WMLs (Brickman et al., 2009). 
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1.1.3. Clinical Implication of White Matter Lesions 
White matter lesions are more common and widely detectable in patients with 
cardiovascular risk factors and symptomatic cerebrovascular disease (Launer, 2004). The 
presence of WMLs can be attributed to several factors. The Rotterdam Scan Study 
(Sarah E. Vermeer et al., 2003) and   Sydney Stroke Study (Wen & Sachdev, 2004) 
documented that individuals with white matter lesions have an increased risk of clinical 
stroke.  In addition to that, larger white matter lesions can actually represent subclinical 
brain infarct (Marshall, Bradley, Marshall, Bhoopat, & Rhodes, 1988). Subcortical silent 
brain infarction which was presented as periventricular hyperintensity and focal WMLs 
is associated with the presence cardiovascular risk factors such as hypertension, diabetes 
and retinal artery sclerosis (Kobayashi, Okada, Koide, Bokura, & Yamaguchi, 1997).  
Incidence of severe WMLs at baseline is an independent predictor of future stroke while 
patients with initially mild WML may develop subsequent stroke as the WML 
progresses (Yamauchi, Fukuda, & Oyanagi, 2002). Similar findings were also reported 
that cerebral WMLs predict both ischemic strokes and myocardial infarctions in patients 
with established atherosclerotic disease (Gerdes et al., 2006). Silent brain infarcts, 
marked periventricular hyperintensity and distinct subcortical white matter lesions are 
important risk factors of clinical stroke. Moreover, silent brain infarcts and marked 
periventricular hyperintensities increase the risk of mortality (Bokura et al., 2006). 
 WMLs also contribute to the cognitive impairment of the patients. In the Rotterdam 
Study (M. M. B. Breteler et al., 1994) elderly individuals with WMLs were associated 
with lower scores on test of cognitive function and were significantly associated with 
subjective mental decline. WMLs and periventricular hyperintensity were significantly 
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more extensive in dementia with lewy bodies than in controls in patients with 
Alzheimers and vascular dementia. Presence of frontal WMLs was associated with 
higher depression scores (Barber et al., 1999). Severity of dementia is directly correlated 
with the amount and size of WML in the periventricular and subcortical regions of the 
brain (Targosz-Gajniak, Siuda, Ochudło, & Opala, 2009b). 
The above data clearly demonstrated that white matter hyperintensities as detected on 
MRI is closely related to vascular events of the brain and in certain instances represent 
subclinical infarcts. Moreover, the degenerative changes of the small vessel salso 
contribute towards the mental and cognitive decline of the patients. 
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1.2. Vitamin E 
1.2.1. Tocotrienol 
Vitamin E consists of eight isomers comprising four tocopherol and four tocotrienol 
isomers, which share similar structural features of a chroman head and a 16-carbon 
phytyl chain. Both tocopherols and tocotrienols are designated as , ,  and , 
depending on the number and positions of methyl groups on the chroman ring (Qureshi 
& Qureshi, 1993). The difference between tocopherols and tocotrienols lie mainly in the 
former having a saturated phytyl chain, while the latter is unsaturated, with 3 double 
bonds at 3', 7' and 11' positions (A. Kamal-Eldin & L. A.  Appelqvist, 1996).Figure 1.1 
shows the general structure of α - tocotrienol. While tocopherols are generally present in 
nuts and common vegetable oils, natural sources of tocotrienols are quite limited, with 
palm oil and rice bran oil containing the highest concentrations of tocotrienols in nature 
(Tan, 1989). 
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Figure 1.1: Chemical structure of tocotrienols 
 
 
 
 
 
 
 
  
8 
 
1.2.2. Neuroprotective Properties 
Much investigation has been carried out to study the neuroprotective properties of 
tocotrienols. Of special significance is the study by (Khanna et al., 2005) which 
demonstrated that tocotrienols introduced into a neuronal cell at nanomolar 
concentrations could prevent glutamate-induced death of neuron cells in mice. The 
underlying mechanism behind the protective properties is through the inhibition of c-Src 
kinase (Sen, Khanna, Roy, & Packer, 2000)and 12-lipoxygenase (Khanna et al., 2003). It 
was also shown that the degeneration of the nerve cells was due to induced stress 
mimicking clinical situations such as ischemia. Therefore, the findings of Khanna et al. 
(2005) implicated that tocotrienols might have a role in the prevention of degenerative 
diseases involving the nervous system. Khanna et al. (2005) showed that tocotrienols 
have in vitro neuroprotective properties. In addition, tocotrienol-supplemented rats 
showed more protection against stroke-inducedinjury compared with matched controls 
(Khanna, et al., 2005). In another study, mongrel canines fed with tocotrienol-enriched 
supplementation significantly attenuated ischemic stroke induced lesion volume. 
Furthermore, it prevented loss of white matter fiber tract connectivity, improved 
cerebrovascular collateral circulation to the ischemic mid cerebral artery territory during 
mid cerebral artery occlusion(Rink et al., 2011). In another study, subjects supplemented 
with self emulsifying preparation of tocotrienol rich vitamin E showed a trend towards 
improvement of arterial compliance which would enable better elasticity and 
sustainability of the blood vessels in the event of stroke (Rasool, Rahman, Yuen, & 
Wong, 2008). 
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1.2.3. Anti-atherogenic Properties 
The development of atherosclerosis involves a multitude of factors both genetic and 
environmental in nature and these include elevated levels of cholesterol especially LDL, 
apolipoprotien B and lipoprotein Lp(a), oxidation of LDL-cholesterol, adhesion 
molecule expression and monocytic cell adherence. The anti-atherogenic activity of -
tocopherol has been linked to its ability to prevent the oxidation of LDL (Esterbauer, 
1991; Salonen, Yia-Hertuala, & Yamamoto, 1992). Nevertheless, this theory remains 
controversial with some studies failing to show association between plasma -
tocopherol levels and reduced mortality from cardiovascular disease(Hense, Stender, 
Bors, & Keil, 1993). Despite the numerous studies carried out on -tocopherol, the 
relationship between tocotrienols and atherosclerosis was investigated only recently. 
These studies demonstrated various benefits of tocotrienols ranging from improving 
lipid profiles [reduced total and LDL cholesterol, apolipoprotein B and lipoprotein 
Lp(a)], lowering of thromboxane B2 and platelet factor 4 levels to reduce LDL oxidation 
(Qureshi et al., 1995; Qureshi, Bradlow, Salser, & Brace, 1997; Qureshi, Qureshi, 
Halser-Raspacz, et al., 1991; Tomeo, Gellar, Watkins, Gapor, & Bierenbaum, 1995) 
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1.2.4. Hypocholesterolemic effect of tocotrienols 
Epidemiological studies have convincingly shown that plasma cholesterol is a major risk 
factor in the development of atherosclerosis as well as cardiovascular diseases such as 
myocardial infarction and coronary heart disease. A high plasma cholesterol 
concentration is associated with a higher risk of cardiovascular diseases (Goldbourt, 
Holtzman, & Nuefeld, 1985). Therefore, reduction of plasma cholesterol is essential in 
lowering the risk (Iso, 1989) and hence decreasing the mortality associated with 
cardiovascular diseases. Reduction of cholesterol can be achieved through restriction of 
cholesterol intake (Chait et al., 1993) and administration of hypocholesterolemic agents. 
The ability of the tocotrienols or tocotrienol rich fraction from palm oil to reduce plasma 
cholesterol is a subject of much investigation (Qureshi, et al., 1995). 
Unlike tocopherols, tocotrienols have been reported to inhibit cholesterol synthesis by 
suppressing 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoAR) activity. 
This effect was ascribed to the unique ability of the isoprenoid side-chain to increase 
cellular farnesol, a mevalonate-derived product. Farnesol in turn down-regulates HMG-
enzyme (Correll, Ng, & Edwards, 1994; Goldstein, 1990). The different isomers of 
tocotrienols exhibit varying degrees of cholesterol lowering activity. In vitro models 
have identified - and -tocotrienol to be more potent than -tocotrienol in suppressing 
cholesterol biosynthesis (Pearce, Parker, Deason, Qureshi, & Wright, 1992). 
A number of studies using animal models (Khor & Chieng, 1997; Qureshi, Qureshi, 
Halser-Raspacz, et al., 1991)and human volunteers (Qureshi, et al., 1995; Qureshi, et al., 
1997; Qureshi, Qureshi, Wright, et al., 1991; Tan, Khor, Low, Ali, & Gapor, 1991)have 
demonstrated the cholesterol-suppressive action of tocotrienols. However, there are 
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studies that show supplementation of tocotrienols had no marked favorable effects on the 
serum lipoprotein profiles in human volunteers with elevated cholesterol levels 
(Mensink, van Houwelingen, Kromhout, & Hornstra, 1999; Mustad, Smith, Ruey, 
Edens, & DeMichele, 2002; Wahlqvist et al., 1992). Nevertheless, Qureshiet al. (1996) 
reported that the relative alpha-tocopherol to the tocotrienol content of more than 30% 
tend to attenuate the cholesterol lowering activity of the tocotrienols. In this regard, it 
should be noted that the preparation used in the study by Wahlqvistet al. (1992) and 
Mensinket al. (1999), had an alpha-tocopherol to tocotrienols ratio of approximately 4:6 
and 3:7 respectively, and might indeed be the reason for the observed negative response.  
In view of the conflicting results, more controlled studies using human volunteers need 
to be carried out to establish the beneficial effects of tocotrienol on cholesterol profiles. 
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1.2.5. Hypo-apolipoprotein B effect of tocotrienols 
Apolipoprotein B (Apo-B), the major structural component of VLDL (very low density 
lipoprotein) and LDL, has been recognized as an independent risk factor for the 
development of premature coronary artery disease (CAD) (Albers, Brunzell, & Med., 
1989). Apo-B appears to be directly involved in the atherosclerotic process as lowering 
Apo-B levels in CAD subjects has resulted in the regression of atherosclerosis (Brown, 
Albers, & Fisher, 1990). Tocotrienols have also been shown to reduce plasma 
apolipoprotein B levels in hypercholesterolemic subjects (Qureshi, et al., 1995; Qureshi, 
Qureshi, Wright, et al., 1991). It is believed that tocotrienols lower plasma Apo-B levels 
partly by up-regulating LDL receptors in the liver, which facilitate the clearance of 
LDL-ApoB from the blood stream (Parker, Pearce, Clark, Gordon, & Wright, 1993). It 
has been suggested that tocotrienols in vitro, in particular -tocotrienol, increase the 
intracellular proteolytic degradation of Apo-B which in turn alter the assembly of VLDL 
with core lipids and its secretion from the liver (Theriault, Wang, Gapor, & Adeli, 1999; 
Wang, Theriault, Gapor, & Adeli, 1998). In short, both the increased clearance rate of 
LDL and the decreased production rate of VLDL cause a reduction of the plasma Apo-B 
levels. Nevertheless, the beneficial reduction of apoB by tocotrienols merit further 
investigation and confirmation. 
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1.2.6. Hypo- lipoprotein Lp (a) effect of tocotrienols 
Lipoprotein (a) [Lp(a)],  a plasma lipoprotein whose structure resembles that of LDL, 
has been found to be the strongest predictor of coronary heart disease (Maher & Brown, 
1995). Elevated plasma levels of Lp(a) is considered atherogenic. When modified by 
lipid peroxidation, it is taken up by macrophages. As a result, cholesterol is deposited 
into macrophages, which forms foam cells within the atherosclerotic lesion 
(Naruszewicz, Selinger, & Davignon, 1992). However, Lp(a) association with 
atherosclerosis is believed to be due to its interference with plasminogen activation 
associated with thrombosis (Miles, Fless, Levin, Scanu, & Plow, 1989). Lowering of 
Lp(a) has not been successful with diet and lipid lowering drugs. However, Qureshiet al. 
(1997) have demonstrated that a novel tocotrienol rich fraction from rice bran oil 
enriched with didesmethyl-tocotrienol (no methyl groups on the chromanol ring) 
decreased plasma Lp(a) levels. This finding also merits further long-term clinical studies 
to verify their beneficial effect in prevention of artherosclerosis. 
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1.2.7. Antioxidant properties of tocotrienols 
The initial step in the pathogenesis of atherosclerosis is believed to be LDL lipid 
peroxidation, which is followed by a cascade of events leading to the formation of foam 
cells in the atherosclerotic lesion (Steinberg, Parthasarathy, Carew, Khoo, & Witztum, 
1989). Tocotrienols, like tocopherols, are free radical scavengers, which owe their 
antioxidative activity to their chain-breaking property that neutralizes peroxyl and 
alkoxyl radicals generated during lipid peroxidation (Burton & Traber, 1990; A. Kamal-
Eldin & L. A.  Appelqvist, 1996). 
Until recently, of all the vitamin E isomers -tocopherol was generally regarded as the 
most potent antioxidant protecting against lipid peroxidation. Serbinovaet al. (1991) 
made remarkable observations that -tocotrienol possessed 40-60 times higher 
antioxidant activity than -tocopherol against Fe2++ascorbate- and Fe2++NADPH-
induced lipid peroxidation in rat liver microsomal membranes and 6.5 times better 
protection of cytochrome P-450 against oxidative damage. Their findings also suggested 
that the higher antioxidant potency was due to -tocotrienol‟s higher recycling 
efficiency from chromanoxyl radicals, its more uniform distribution in membrane bilayer 
and its stronger disordering of membrane lipids, enabling better interaction of 
chromanols with lipid radicals. In addition, Kamat and Devasagayam (1995)also 
reported a significant inhibition of oxidative damage in vitro to both lipids and proteins 
in rat brain mitochondria with -tocotrienol showing superior activity compared to the 
other tocotrienols.  
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1.2.8. Inhibition of adhesion molecule expression and monocytic cell 
adherence by tocotrienols 
Monocytic adherence to endothelium of blood vessels, mediated by multiple cell 
adhesion molecules, including ICAM-1, VCAM-1 and E-selectin(Carlos & Harlan, 
1994)has been shown to be critical in the development of atherosclerosis. Enhanced 
over-expression of these surface molecules has been shown to be stimulated by 
oxidized LDL but down regulated by antioxidants (Khan, Parthasarthy, Alexander, & 
Medford, 1995). -tocopherol has been shown to reduce endothelial adhesion 
molecule expression and monocytic cell adherence (Devaraj, Li, & Jialal, 1996) but 
the effect of tocotrienols was only recently investigated. Theriault et al. (2002) 
reported that -tocotrienol was the most effective form of vitamin E for reducing 
endothelial expression of adhesion molecules and adhesion to monocytes when they 
compared 3 forms of vitamin E, -tocopherol, -tocopheryl succinate and -
tocotrienol. 
In view of the neuroprotective and anti-atherogenic potential of tocotrienol rich 
fraction through the various mechanisms mentioned above, the protective effects of 
tocotrienols on progression of sub-clinical white matter lesions and carotid artery 
stenosis in humans deserve further investigation and confirmation.  
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1.3. Clinical Evaluations: Basic Principles of Magnetic Resonance Imaging of the 
Brain 
An MRI is a noninvasive approach that produces cross-sectional images of the body.  
Images of the brain, spine, joints, abdomen, and pelvis are generated using a strong 
magnetic field and radio waves to produce very clear and detailed computerized 
images of the inside of the body.  Its efficacy as a clinical imaging modality is based 
primarily upon humans being proton-rich; the tissues are composed of between 70% 
and 90% water, which is concentrated hydrogen nuclei or protons. MRI images are 
obtained by measuring how rapidly hydrogen nuclei of different tissues return to 
their resting energy states after being excited by a strong magnetic field (McRobbie, 
Moore, Graves, & Prince, 2003). 
The properties and amount of water within a tissue can alter drastically with disease 
or injury; MRI is very sensitive to the former and, therefore, a very sensitive 
diagnostic modality. MRI images display a better definition between the lesion and 
the adjacent normal tissue than other imaging modalities (Silvers, 2006). T1 scans 
are often known as „anatomy scans‟, because their images display excellent contrast, 
and most clearly show the boundaries between different tissues. T2 images take 
longer to acquire than T1 images. T2 images are often termed „pathology scans‟ 
because collections of abnormal fluid are bright against the darker normal tissue 
(McRobbie, et al., 2003). On a T2-weighted scan, water- and fluid-containing tissues 
are bright and fat-containing tissues are dark. The reverse is true for T1-weighted 
images. Damaged tissue tends to develop edema, which makes a T2-weighted 
sequence sensitive for pathology, and generally able to distinguish pathologic tissue 
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from normal tissue. With the addition of an additional radio frequency pulse and 
additional manipulation of the magnetic gradients, a T2-weighted sequence can be 
converted to a FLAIR sequence, in which free water is now dark, but edematous 
tissues remain bright. This sequence is currently the most sensitive way to evaluate 
the brain for demyelinating diseases (Rinck, 2012). 
MRI of the carotid blood vessels which is also referred as Magnetic Resonance 
angiography (MRA). The blood vessels in the neck (carotid and vertebral arteries) 
and brain are frequently studied by MRA to look for areas of constriction 
(narrowing) or dilatation (widening). 
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1.4. Scope of the study 
The nonexistence of a proper treatment for WMLs has led to the initiation of the 
current clinical trial which is the first and largest human study to propose a 
treatment for such condition. The objectives of the study are: 
1.4.1. Primary Objective 
To assess the neuroprotective properties of tocotrienols supplementation as 
determined by white matter lesion load on serial MRI. 
1.4.2. Secondary Objectives 
a) To evaluate the anti-atherogenic effects of tocotrienols supplementation with 
serial carotid artery MRA. 
b) To determine the effects of tocotrienols on blood parameters including total lipid 
profile (LDL and HDL subfractions), Apo-B, C-reactive protein, antioxidant 
profile, Lp(a) and lipid peroxidation. 
c) To determine the prevalence of WML in a local hypercholesterolemic population 
in northwest peninsular Malaysia. 
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2. CHAPTER 2: MAGNETIC RESONANCE ANGIOGRAPHY OF THE 
CAROTID ARTERY STENOSIS AMONG MILDLY 
HYPERCHOLESTEROLEMIC VOLUNTEERS 
 
2.1.  Introduction 
Carotid arteries are two large blood vessels in the neck that supplies brain with blood. In 
the presence of carotid artery disease, the arteries become narrow, usually because of 
atherosclerosis. Atherosclerosis (or arteriosclerotic vascular disease) is a condition 
where the arteries become narrowed and hardened due to an excessive build up of plaque 
around the artery wall. The disease disrupts the flow of blood around the body, posing 
serious cardiovascular and cerebrovascular complications such as myocardial infarction 
and stroke.  
The current gold standard of imaging carotid artery stenosis is digital subtraction 
angiography (DSA). However, DSA has a risk of morbidity and mortality which 
includes transient ischaemic attack, minor stroke or a small risk of death (<1%) (Davies 
& Humphrey, 1993; Hankey, Warlow, & Molyneux, 1990).The other option of 
conducting the carotid artery imaging is by magnetic resonance angiography (MRA) or 
duplex ultrasound (DUS). Both methods are non invasive. In a preoperative diagnostic 
study by Nederkoorn et al. (2002) and a subsequent metanalysis by Nederkoorn et 
al.(2003), MRA was shown to have a better accuracy than DUS in diagnosing carotid 
artery stenosis. Thus, MRA of the carotid artery was preferred to assess the presence of 
stenosis in our subject population. The aim of the study was to evaluate the anti-
atherogenic effects of mixed tocotrienols supplementation with serial carotid artery 
20 
 
MRA. A pilot study carried out by Kooyenga et al. (1997b) investigated the protective 
effects of a tocotrienol and tocopherol enriched palm oil in patients with carotid stenosis. 
Apart from measuring the various blood atherogenic indicators, they also monitored the 
changes in the degree of carotid artery stenosis using duplex carotid ultrasonography. 
After 2 years follow up, they found carotid atherosclerotic regression in 8 and 
progression in 2 of the 25 patients receiving the palm vitamin E preparation, while none 
of the control group exhibited regression and 10 of the 25 patients showed progression 
(p<0.01). Moreover, the serum thiobarbituric acid reactive substance (TBARS) 
decreased for patients in the treatment group (p<0.05) while there was no change for 
patients in the placebo group, indicating that the anti-atherogenic effect of palm vitamin 
E might be attributed to their antioxidant properties and protection against lipid 
peroxidation. In view of this encouraging outcome, the MRA of the carotid artery was 
conducted in this study to assess the anti atherogenic effect of mixed tocotrienols in a 
mildly hypercholesterolemic volunteers using MRA as a preferred method of imaging. 
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2.2. Materials and methods 
2.2.1. Study Population 
Data sets were obtained from the initial 50 consecutively selected volunteers (mean age 
48 ± 6.4 years, 27 males and 23 females) scheduled  for the brain MRI  WML study, 
were also subjected to undergo the MRA of the carotid artery. Informed consent was 
obtained from all volunteers, and the study was approved by the Research Ethics 
Committee for Human Studies of Universiti Sains Malaysia 
(http://www.crp.kk.usm.my/pages/jepem.htm). The volunteers were recruited if they had 
one or more of the following criteria; total cholesterol level between 5.2 – 6.2 mmol/L 
and low-density cholesterol level between 2.6 – 4.2 mmol/L, body mass index (BMI) of 
more than 25kg/m
2
, hypertension (according to Joint National Committee 7 guidelines, 
2003) or diabetes mellitus under medical supervision and treatment and their levels are 
under control. Apart from the above criteria, the volunteers should display normal liver 
and renal functions. Volunteers were excluded if they have consumed vitamin E 
supplementation within the past 3 months at the time of recruitment, known history of 
hypersensitivity to vitamin E, pregnant females, unable to comply to the study protocol, 
history of drug dependence or drug abuse, undergoing antihyperlipidemic treatment and 
contraindicated for the brain MRI and MRA screening such as claustrophobia and 
presence of metal implants in their body. Baseline assessment of demographic profile 
(age, race, present disease) and clinical parameters (TC, LDL, HDL, Apo B, LP (A), TG, 
HsCRP, ALT, ALP, AST, CRT, GGT, BMI, fasting glucose and blood pressure) were 
documented and are shown in table 2.1. 
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2.2.2. MRA Imaging Procedures 
All patients were imaged on a 1.5T MRI scanner (Model Signa HDx, General Electric, 
Milwaukee, USA) using a HD 8 ch NV array (In vivo corporation, Pewaukee 
Wisconsin) radiofrequency coil using specially-designed, phased-array surface coils.  
The examination included sequences of axial 2D spoiled gradient-recalled echo, T1-
weighted images of the carotid artery at 5 to 7 locations, centered on the carotid 
bifurcation. The imaging parameters were as follows: repetition time (TR), 100 ms; echo 
time (TE), 3.5 ms; flip, 60°; thickness, 3 mm; gap, 1 mm; field-of-view, 1612 cm; and 
matrix, 256144. Each acquisition was repeated 10 times, with a repetition interval of 15 
seconds. Coincident with the second image in the sequence, 0.1 mmol/kg (0.2 mL/kg) 
gadolinium-based contrast agent (Omniscan, Amersham Health) was injected at a rate of 
2 mL/s via a power injector. After acquisition, one location per patient was selected for 
analysis. The primary criteria for selection were the presence of a large atherosclerotic 
plaque and clear delineation of the lumen and outer wall boundaries of the artery. If 
more than one location met these criteria, the one closest to the bifurcation was selected 
to facilitate matching with histological specimens. Each selected image sequence was 
then individually post processed with the Kalman Filtering Registration and Smoothing 
(KFRS) algorithm, which reduced patient motion and noise in the image sequences. 
Finally, contours were drawn around the carotid lumen and just inside the outer wall 
boundary using the first image after contrast agent arrival in the carotid lumen. The outer 
contour was carefully drawn to exclude the adventitia, thereby limiting the analysis 
region to the plaque itself. Contrast agent kinetics was analyzed for the plaque region 
between contours.    
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2.2.3. Image Analysis 
One reader (consultant radiologist) with 16 years of experience, blinded to clinical 
information and results of other diagnostic tests reviewed all contrast-enhanced MR 
angiographic studies. Patient identifiers were masked. Image analysis was performed 
and the subjects were randomized and evaluated. The contrast enhanced MR angiograms 
were the evaluated using Osirix (Rosset, Spadola, & Ratib, 2004) and each left and right 
internal carotid artery (ICA) was evaluated as an independent unit. 
For each study, the reader first chose the projection that demonstrated any stenosis. It is 
done initially by subjective visual impression. Four measurements were then made: (1) 
luminal diameter of the normal distal ICA beyond the bulb where the artery wall 
becomes parallel; (2) luminal diameter at the site of maximal narrowing; (3) luminal 
diameter of the estimated original width of the artery at the site of maximal narrowing; 
and, finally, (4) luminal diameter of the proximal disease-free common carotid artery 
(CCA) where the artery wall becomes parallel. The calculation of percentage stenosis 
was performed using North American Symptomatic Trial Collaborators (NASCET) 
method as illustrated in figure 2.1. Stenosis was classified as mild (0% to49%), moderate 
(50% to 69%), severe (70% to 99%), or complete occlusion (U-King-Im et al., 2004). 
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Figure 2.1: Diagram of an ICA stenosis illustrating measurement method (Adapted  
from North American Symptomatic Carotid Endartectomy Trial (NASCET) Steering 
Committee 1991) 
 
 
2.2.4. Statistical Analysis 
 
All the statistical analysis were conducted using Statistical Package for Social Sciences 
(IBM SPSS) software version 19.The homogeneity of the baseline characteristics (table 
2.1) between the two groups was assessed using an independent Student's ttest. A chi 
square test was used to assess the association of disease profile between male and female 
volunteers (table 2.2). A statistically significant difference was considered at p < 0.05. 
 
 
 
 
 
 
